Royalty Pharma Plc (RPRX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1236218,
    "name": "Royalty Pharma Plc",
    "stock_name": "Royalty Pharma Plc",
    "full_name": "Royalty Pharma Plc",
    "name_url": "stocks-analysis/royalty-pharma-plc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "39.15",
    "chg": -0.38,
    "chgp": "-0.96%",
    "dir": -1,
    "prev_price": "39.53",
    "mcapval": "20,879.42",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "GB00BMVP7Y09",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "8.8 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/royalty-pharma-plc-1236218-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Royalty Pharma Plc overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-royalty-pharma-plc-overvalued-or-undervalued-3711452",
        "imagepath": "",
        "date": "2025-11-18 11:14:53",
        "description": "As of 14 November 2025, the valuation grade for Royalty Pharma Plc moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 11, a Price to Book Value of 2.84, and an EV to EBITDA of 13.43. In comparison, its peer Incyte Corp. has a significantly higher P/E ratio of 22.95, suggesting that Royalty Pharma may offer a more attractive entry point for investors.\n\nDespite recent strong performance, with a year-to-date return of 53.51% compared to the S&P 500's 14.49%, the company's long-term returns have lagged, particularly over the past three and five years. This contrast highlights the potential for recovery and growth in the near term, supporting the view that Royalty Pharma is fairly valued at present...."
      },
      {
        "title": "Is Royalty Pharma Plc overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-royalty-pharma-plc-overvalued-or-undervalued-3706980",
        "imagepath": "",
        "date": "2025-11-17 11:08:53",
        "description": "As of 14 November 2025, the valuation grade for Royalty Pharma Plc has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 11, a Price to Book Value of 2.84, and an EV to EBITDA of 13.43. In comparison, Incyte Corp. shows a higher P/E of 22.95, indicating that Royalty Pharma may be more attractively priced relative to its peer.\n\nDespite recent stock performance, where Royalty Pharma has outperformed the S&P 500 with a year-to-date return of 53.51% compared to the S&P 500's 14.49%, the long-term returns over 3 and 5 years have lagged significantly. This suggests that while the company is currently fairly valued, its historical performance may warrant a cautious approach for potential investors...."
      },
      {
        "title": "Is Royalty Pharma Plc overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-royalty-pharma-plc-overvalued-or-undervalued-3705620",
        "imagepath": "",
        "date": "2025-11-16 11:05:33",
        "description": "As of 14 November 2025, the valuation grade for Royalty Pharma Plc moved from expensive to fair. The company is currently fairly valued, with a P/E ratio of 11, a Price to Book Value of 2.84, and an EV to EBITDA of 13.43. In comparison, its peer Incyte Corp. has a significantly higher P/E ratio of 22.95, indicating that Royalty Pharma may offer better value relative to its earnings.\n\nDespite recent strong performance, with a year-to-date return of 53.51% compared to the S&P 500's 14.49%, the company's long-term returns over three and five years have lagged significantly behind the index. This suggests that while Royalty Pharma is currently fairly valued, caution may be warranted for long-term investors given its historical performance trends...."
      },
      {
        "title": "Royalty Pharma Hits Day High with 8.36% Surge in Strong Intraday Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/royalty-pharma-hits-day-high-with-836-surge-in-strong-intraday-performance-3676168",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/RoyaltyPharmaPl_priceRelatedfactors_3676168.png",
        "date": "2025-11-06 16:25:00",
        "description": "Royalty Pharma Plc's stock surged on November 5, 2025, reaching an intraday high and outperforming the S&P 500 over the past week. The company has seen substantial annual growth, though it faces challenges with a decline in operating profit over the last five years. Financial metrics indicate a solid market position."
      },
      {
        "title": "Royalty Pharma Plc Hits New 52-Week High of $38.09",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/royalty-pharma-plc-hits-new-52-week-high-of-3809-3674061",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/RoyaltyPharmaPl_priceRelatedfactors_3674061.png",
        "date": "2025-11-05 16:53:15",
        "description": "Royalty Pharma Plc achieved a new 52-week high of USD 38.09 on November 4, 2025, marking a significant increase of 38.15% over the past year. This performance highlights the company's strong position in the pharmaceuticals and biotechnology sector, contrasting with the S&P 500's 19.89% gain during the same timeframe."
      },
      {
        "title": "Is Royalty Pharma Plc technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-royalty-pharma-plc-technically-bullish-or-bearish-3673778",
        "imagepath": "",
        "date": "2025-11-05 11:24:53",
        "description": "As of 31 October 2025, the technical trend for Royalty Pharma Plc has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD and KST also support a bullish outlook. However, the weekly MACD and KST are mildly bearish, suggesting some short-term weakness. The Bollinger Bands are mildly bullish on a monthly basis, and Dow Theory shows a mildly bullish trend for both weekly and monthly periods. \n\nIn terms of performance, Royalty Pharma has outperformed the S&P 500 over the past week (1.56% vs. 0.71%), the past month (4.91% vs. 1.92%), and year-to-date (48.33% vs. 16.30%), but has underperformed over the longer three-year and five-year periods. Overall, the current technical stance is bullish, with a strong emphasis on the daily moving averages and monthly indicators...."
      },
      {
        "title": "Royalty Pharma Plc Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/royalty-pharma-plcs-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-strong-performance-3671403",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/RoyaltyPharmaPl_technicaldot_3671403.png",
        "date": "2025-11-04 16:04:35",
        "description": "Royalty Pharma Plc has recently revised its evaluation amid changing market dynamics. The stock, priced at $37.30, has shown a strong one-year performance with a 37.64% return, significantly surpassing the S&P 500. However, longer-term returns over three and five years indicate a decline."
      },
      {
        "title": "Is Royalty Pharma Plc technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-royalty-pharma-plc-technically-bullish-or-bearish-3664677",
        "imagepath": "",
        "date": "2025-11-02 11:20:20",
        "description": "As of 31 October 2025, the technical trend for Royalty Pharma Plc has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD and Bollinger Bands also support this bullish outlook. However, the weekly MACD and KST are mildly bearish, and the Dow Theory shows a mixed signal with a mildly bullish weekly and mildly bearish monthly stance. Overall, the technical stance is bullish but with some caution due to the mixed signals on the weekly indicators.\n\nIn terms of performance, Royalty Pharma has outperformed the S&P 500 in the 1-week (0.75% vs. 0.71%), 1-month (3.36% vs. 1.92%), and year-to-date (47.16% vs. 16.30%) periods, but has underperformed over the longer 3-year, 5-year, and 10-year periods...."
      },
      {
        "title": "Royalty Pharma Plc Experiences Evaluation Revision Amidst Mixed Market Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/royalty-pharma-plcs-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-price-increase-3652092",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/RoyaltyPharmaPl_technicaldot_3652092.png",
        "date": "2025-10-28 15:46:54",
        "description": "Royalty Pharma Plc has recently revised its evaluation amid changing market dynamics. The stock is priced at $37.26, reflecting a year-to-date return of 46.06%. Despite strong annual performance, longer-term returns over three and five years show declines, indicating challenges ahead."
      }
    ],
    "total": 19,
    "sid": "1236218",
    "stock_news_url": "https://www.marketsmojo.com/news/royalty-pharma-plc-1236218"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Royalty Pharma Plc overvalued or undervalued?

2025-11-18 11:14:53

As of 14 November 2025, the valuation grade for Royalty Pharma Plc moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 11, a Price to Book Value of 2.84, and an EV to EBITDA of 13.43. In comparison, its peer Incyte Corp. has a significantly higher P/E ratio of 22.95, suggesting that Royalty Pharma may offer a more attractive entry point for investors. Despite recent strong performance, with a year-to-date return of 53.51% compared to the S&P 500's 14.49%, the company's long-term returns have lagged, particularly over the past three and five years. This contrast highlights the potential for recovery and growth in the near term, supporting the view that Royalty Pharma is fairly valued at present....

Is Royalty Pharma Plc overvalued or undervalued?

2025-11-17 11:08:53

As of 14 November 2025, the valuation grade for Royalty Pharma Plc has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 11, a Price to Book Value of 2.84, and an EV to EBITDA of 13.43. In comparison, Incyte Corp. shows a higher P/E of 22.95, indicating that Royalty Pharma may be more attractively priced relative to its peer. Despite recent stock performance, where Royalty Pharma has outperformed the S&P 500 with a year-to-date return of 53.51% compared to the S&P 500's 14.49%, the long-term returns over 3 and 5 years have lagged significantly. This suggests that while the company is currently fairly valued, its historical performance may warrant a cautious approach for potential investors....

Is Royalty Pharma Plc overvalued or undervalued?

2025-11-16 11:05:33

As of 14 November 2025, the valuation grade for Royalty Pharma Plc moved from expensive to fair. The company is currently fairly valued, with a P/E ratio of 11, a Price to Book Value of 2.84, and an EV to EBITDA of 13.43. In comparison, its peer Incyte Corp. has a significantly higher P/E ratio of 22.95, indicating that Royalty Pharma may offer better value relative to its earnings. Despite recent strong performance, with a year-to-date return of 53.51% compared to the S&P 500's 14.49%, the company's long-term returns over three and five years have lagged significantly behind the index. This suggests that while Royalty Pharma is currently fairly valued, caution may be warranted for long-term investors given its historical performance trends....

Royalty Pharma Hits Day High with 8.36% Surge in Strong Intraday Performance

2025-11-06 16:25:00

Royalty Pharma Plc's stock surged on November 5, 2025, reaching an intraday high and outperforming the S&P 500 over the past week. The company has seen substantial annual growth, though it faces challenges with a decline in operating profit over the last five years. Financial metrics indicate a solid market position.

Royalty Pharma Plc Hits New 52-Week High of $38.09

2025-11-05 16:53:15

Royalty Pharma Plc achieved a new 52-week high of USD 38.09 on November 4, 2025, marking a significant increase of 38.15% over the past year. This performance highlights the company's strong position in the pharmaceuticals and biotechnology sector, contrasting with the S&P 500's 19.89% gain during the same timeframe.

Is Royalty Pharma Plc technically bullish or bearish?

2025-11-05 11:24:53

As of 31 October 2025, the technical trend for Royalty Pharma Plc has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD and KST also support a bullish outlook. However, the weekly MACD and KST are mildly bearish, suggesting some short-term weakness. The Bollinger Bands are mildly bullish on a monthly basis, and Dow Theory shows a mildly bullish trend for both weekly and monthly periods. In terms of performance, Royalty Pharma has outperformed the S&P 500 over the past week (1.56% vs. 0.71%), the past month (4.91% vs. 1.92%), and year-to-date (48.33% vs. 16.30%), but has underperformed over the longer three-year and five-year periods. Overall, the current technical stance is bullish, with a strong emphasis on the daily moving averages and monthly indicators....

Royalty Pharma Plc Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators

2025-11-04 16:04:35

Royalty Pharma Plc has recently revised its evaluation amid changing market dynamics. The stock, priced at $37.30, has shown a strong one-year performance with a 37.64% return, significantly surpassing the S&P 500. However, longer-term returns over three and five years indicate a decline.

Is Royalty Pharma Plc technically bullish or bearish?

2025-11-02 11:20:20

As of 31 October 2025, the technical trend for Royalty Pharma Plc has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD and Bollinger Bands also support this bullish outlook. However, the weekly MACD and KST are mildly bearish, and the Dow Theory shows a mixed signal with a mildly bullish weekly and mildly bearish monthly stance. Overall, the technical stance is bullish but with some caution due to the mixed signals on the weekly indicators. In terms of performance, Royalty Pharma has outperformed the S&P 500 in the 1-week (0.75% vs. 0.71%), 1-month (3.36% vs. 1.92%), and year-to-date (47.16% vs. 16.30%) periods, but has underperformed over the longer 3-year, 5-year, and 10-year periods....

Royalty Pharma Plc Experiences Evaluation Revision Amidst Mixed Market Indicators

2025-10-28 15:46:54

Royalty Pharma Plc has recently revised its evaluation amid changing market dynamics. The stock is priced at $37.26, reflecting a year-to-date return of 46.06%. Despite strong annual performance, longer-term returns over three and five years show declines, indicating challenges ahead.

View All News